Endothelin receptor antagonists in proteinuric renal disease: every rose has its thorn.
作者信息
Ritz Eberhard, Wenzel René
出版信息
J Am Soc Nephrol. 2010 Mar;21(3):392-4. doi: 10.1681/ASN.2010010047. Epub 2010 Feb 4.
Abstract
摘要
相似文献
1
Endothelin receptor antagonists in proteinuric renal disease: every rose has its thorn.蛋白尿性肾病中的内皮素受体拮抗剂：每朵玫瑰都有刺。
J Am Soc Nephrol. 2010 Mar;21(3):392-4. doi: 10.1681/ASN.2010010047. Epub 2010 Feb 4.
2
Target-Mediated Population Pharmacokinetic Modeling of Endothelin Receptor Antagonists.内皮素受体拮抗剂的基于靶标的群体药代动力学模型构建。
Pharm Res. 2019 Dec 10;37(1):2. doi: 10.1007/s11095-019-2723-3.
3
The endothelin system and endothelin receptor antagonists.内皮素系统和内皮素受体拮抗剂。
Curr Opin Nephrol Hypertens. 2012 Jan;21(1):66-71. doi: 10.1097/MNH.0b013e32834dde48.
4
Effects of nonpeptide endothelin receptor antagonists in rats with reduced renal mass.非肽类内皮素受体拮抗剂对肾质量减少大鼠的影响。
J Cardiovasc Pharmacol. 1999 Apr;33(4):611-8. doi: 10.1097/00005344-199904000-00014.
5
Dose-dependent acute and sustained renal effects of the endothelin receptor antagonist avosentan in healthy subjects.内皮素受体拮抗剂阿伏生坦在健康受试者中剂量依赖性的急性和持续性肾脏效应。
Clin Pharmacol Ther. 2009 Jun;85(6):628-34. doi: 10.1038/clpt.2009.15. Epub 2009 Mar 11.
6
Reversal of proteinuric renal disease and the emerging role of endothelin.蛋白尿性肾病的逆转及内皮素的新作用
Nat Clin Pract Nephrol. 2008 Sep;4(9):490-501. doi: 10.1038/ncpneph0891. Epub 2008 Jul 22.
7
Avosentan for overt diabetic nephropathy.阿伏生坦治疗显性糖尿病肾病。
J Am Soc Nephrol. 2010 Mar;21(3):527-35. doi: 10.1681/ASN.2009060593. Epub 2010 Feb 18.
8
Effect of endothelin-receptor antagonists on delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage remains unclear.内皮素受体拮抗剂对动脉瘤性蛛网膜下腔出血后迟发性脑缺血的影响仍不清楚。
Stroke. 2009 Dec;40(12):e714; author reply e715-6. doi: 10.1161/STROKEAHA.109.565887. Epub 2009 Oct 29.
9
Therapeutic potential of endothelin receptor antagonists for chronic proteinuric renal disease in humans.内皮素受体拮抗剂对人类慢性蛋白尿性肾病的治疗潜力。
Biochim Biophys Acta. 2010 Dec;1802(12):1203-13. doi: 10.1016/j.bbadis.2010.03.012. Epub 2010 Mar 30.
10
Endothelin research and the discovery of macitentan for the treatment of pulmonary arterial hypertension.内皮素研究与马西替坦治疗肺动脉高压的发现。
Am J Physiol Regul Integr Comp Physiol. 2016 Oct 1;311(4):R721-R726. doi: 10.1152/ajpregu.00475.2015. Epub 2016 Aug 17.
引用本文的文献
1
Plasma pro-endothelin-1 peptide concentrations rise in chronic kidney disease and following selective endothelin A receptor antagonism.慢性肾脏病患者以及选择性内皮素A受体拮抗治疗后，血浆前内皮素-1肽浓度升高。
J Am Heart Assoc. 2015 Mar 23;4(3):e001624. doi: 10.1161/JAHA.114.001624.
2
Chronic kidney disease: a new look at pathogenetic mechanisms and treatment options.慢性肾脏病：对发病机制和治疗选择的新认识。
Pediatr Nephrol. 2014 May;29(5):779-92. doi: 10.1007/s00467-013-2436-5. Epub 2013 Mar 8.
3
Limitations and future treatment options in type 2 diabetes with renal impairment.2型糖尿病合并肾功能损害的局限性及未来治疗选择
Diabetes Care. 2011 May;34 Suppl 2(Suppl 2):S330-4. doi: 10.2337/dc11-s242.
4
Hypertension in 2010: Blood pressure and the kidney.2010 年高血压：血压与肾脏。
Nat Rev Nephrol. 2011 Feb;7(2):73-4. doi: 10.1038/nrneph.2010.189.
本文引用的文献
1
Avosentan for overt diabetic nephropathy.阿伏生坦治疗显性糖尿病肾病。
J Am Soc Nephrol. 2010 Mar;21(3):527-35. doi: 10.1681/ASN.2009060593. Epub 2010 Feb 18.
2
A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial.一种用于降低顽固性高血压患者血压的选择性内皮素受体拮抗剂：一项随机、双盲、安慰剂对照试验。
Lancet. 2009 Oct 24;374(9699):1423-31. doi: 10.1016/S0140-6736(09)61500-2. Epub 2009 Sep 11.
3
Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes.与单独使用每种药物不同，赖诺普利与阿伏生坦联合使用可促进实验性糖尿病中肾脏病变的消退。
Am J Physiol Renal Physiol. 2009 Nov;297(5):F1448-56. doi: 10.1152/ajprenal.00340.2009. Epub 2009 Aug 12.
4
Effects of endothelin receptor antagonism relate to the degree of renin-angiotensin system blockade in chronic proteinuric kidney disease.内皮素受体拮抗作用的效果与慢性蛋白尿性肾病中肾素-血管紧张素系统阻断的程度相关。
Hypertension. 2009 Sep;54(3):e19-20. doi: 10.1161/HYPERTENSIONAHA.109.138263. Epub 2009 Aug 3.
5
The selective vitamin D receptor activator for albuminuria lowering (VITAL) study: study design and baseline characteristics.降低蛋白尿的选择性维生素 D 受体激动剂（VITAL）研究：研究设计和基线特征。
Am J Nephrol. 2009;30(3):280-6. doi: 10.1159/000225903. Epub 2009 Jun 15.
6
Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-a receptor antagonism in chronic kidney disease.慢性肾脏病患者急性内皮素-A受体拮抗后，蛋白尿和动脉僵硬度的降低与血压无关
Hypertension. 2009 Jul;54(1):113-9. doi: 10.1161/HYPERTENSIONAHA.109.132670. Epub 2009 Jun 8.
7
Dose-dependent acute and sustained renal effects of the endothelin receptor antagonist avosentan in healthy subjects.内皮素受体拮抗剂阿伏生坦在健康受试者中剂量依赖性的急性和持续性肾脏效应。
Clin Pharmacol Ther. 2009 Jun;85(6):628-34. doi: 10.1038/clpt.2009.15. Epub 2009 Mar 11.
8
Thiazolidinedione-induced fluid retention is independent of collecting duct alphaENaC activity.噻唑烷二酮类药物引起的液体潴留与集合管α-上皮钠通道活性无关。
J Am Soc Nephrol. 2009 Apr;20(4):721-9. doi: 10.1681/ASN.2008040415. Epub 2009 Jan 21.
9
Avosentan reduces albumin excretion in diabetics with macroalbuminuria.阿伏生坦可减少患有大量白蛋白尿的糖尿病患者的白蛋白排泄。
J Am Soc Nephrol. 2009 Mar;20(3):655-64. doi: 10.1681/ASN.2008050482. Epub 2009 Jan 14.
10
Aliskiren combined with losartan in type 2 diabetes and nephropathy.阿利吉仑与氯沙坦联合用于2型糖尿病和肾病
N Engl J Med. 2008 Jun 5;358(23):2433-46. doi: 10.1056/NEJMoa0708379.
Zotero 插件